Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: Neuropharmacology. 2016 Nov 25;114:156–167. doi: 10.1016/j.neuropharm.2016.11.015

Figure 3.

Figure 3

Cannabinoid receptors mediate the anti-edematous and anti-allodynic effects of SA-57 (5 mg/kg, i.p.) in the carrageenan model of inflammatory pain. (A) SA-57 reverses allodynia in CB1 (+/+) mice, but not in CB1 (−/−) mice. (B) SA-57 retains its anti-edematous effects in CB1 (−/−) and (+/+) mice. SA-57 reverses carrageenan-induced allodynia (C) and edema (D) in CB2 (+/+) mice, but not in CB1 (−/−) mice. *** p<0.0001, ** p<0.001, * p < 0.05 vs. vehicle, ## p<0.001, ### p < 0.0001 vs. WT + SA-57. Data reflect mean ± SEM, n=6 mice per group.